New surgical technique is effective for keratoconus

Article

For the management of keratoconus, diamond-knife?assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a recently published study.

For the management of keratoconus, diamond-knife–assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a study recently published in the Journal of Cataract & Refractive Surgery.

Diamond-knife–assisted DALK is the most recent variation of DALK for cornea replacement, and is preceded by the big-bubble technique, in which air is injected into the corneal stroma to isolate Desçemet's membrane.

Researchers performed diamond-knife–assisted DALK in 19 eyes and big-bubble DALK in 11 eyes successfully. At 6 months, mean corrected distance visual acuity (CDVA) improved significantly, from 1.87 logMAR to 0.23 logMAR (P = 0.05). In addition, mean keratometry improved from 65.99 D to 45.13 D, and the mean keratometric cylinder improved from 7.99 D to 2.87 D (P = 0.05 for both).

Postoperatively, mean refractive astigmatism was 2.55 D and the mean spherical equivalent was -1.97 D. When comparisons were made between diamond-knife–assisted DALK and big-bubble DALK, the following values were comparable: CDVA (P = 0.06), postoperative keratometry (P = 0.64), refractive cylinder (P = 0.63), and endothelial cell loss (P = 0.11).

All surgeries were completed successfully, and there were no intraoperative or postoperative complications with the diamond-knife–assisted DALK.

To access the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.